Substantial fibrin amyloidogenesis in type 2 diabetes assessed using amyloid-selective fluorescent stains

Ethereia Pretorius1*, Martin J. Page1, Lize Engelbrecht2, Graham C. Ellis1,3 and Douglas B. Kell1,4*

Abstract

Background: We have previously shown that many chronic, inflammatory diseases are accompanied, and possibly partly caused or exacerbated, by various coagulopathies, manifested as anomalous clots in the form of ‘dense matted deposits’. More recently, we have shown that these clots can be amyloid in nature, and that the plasma of healthy controls can be induced to form such clots by the addition of tiny amounts of bacterial lipopolysaccharide or lipoteichoic acid. Type 2 diabetes (T2D) is also accompanied by raised levels of LPS.

Methods: We use superresolution and confocal microscopies to investigate the amyloid nature of clots from healthy and T2D individuals.

Results: We show here, with the established stain thioflavin T and the novel stains Amytracker™ 480 and 680, that the clotting of plasma from type 2 diabetics is also amyloid in nature, and that this may be prevented by the addition of suitable concentrations of LPS-binding protein.

Conclusion: This implies strongly that there is indeed a microbial component to the development of type 2 diabetes, and suggests that LBP might be used as treatment for it and its sequelae.

Introduction

Inflammation is characterised by dysregulated circulating pro-inflammatory molecules, and such molecules have a pathological effect on the haematological system. This is true not only of the immune cells, but also of erythrocytes (RBCs), platelets and plasma proteins such as fibrin(ogen). During inflammation, RBCs experience structural and biochemical changes, which include membrane changes that may be visible as agglutination, eryptosis or microparticle formation [1–7]. In addition, the structure of the fibrin(ogen) protein changes, and this results in anomalous clot formation when fibrinogen is hydrolysed by thrombin [8–11]. Haematological pathology therefore both reflects and is reflected by a pro-coagulant state, which is a hallmark both of inflammation and of the concomitant dysregulated profile of circulating pro-inflammatory molecules [8].

Type 2 diabetes (T2D) is an inflammatory condition that is also characterised by various dysregulated cytokines and other molecules that are immunomodulatory and of pathophysiological importance [12, 13]. This condition is accompanied by many cardiovascular complications, including a thrombotic propensity; however, the inflammatory stimulus is often unknown. Importantly, T2D plasma has aberrant fibrin(ogen) packaging, and this is associated with amyloid fibril formation, as demonstrated by the amyloid-selective stain thioflavin T (ThT) (see [14, 15]) that binds to anomalous clots prepared by adding thrombin to diabetic plasma.

We have recently highlighted the possible and potent role of the circulating bacterial-derived inflammagens lipopolysaccharide (LPS) and lipoteichoic acids (LTAs) on anomalous blood hypercoagulation. LPSs derive from the membranes of Gram-negative bacteria [16], while...
LTAs originate from membranes of Gram-positives [17]. Importantly, the literature does support the increased circulating LPS in T2D [18–25].

LPS and LTA added to healthy plasma cause amyloidogenic changes in fibrin(ogen), demonstrated by thioflavin T (ThT) binding as well as binding of luminescent conjugated oligothiophene dyes (LCOs), marketed under the trade name Amytracker™, that also stain classical amyloid structures [11]. Various fluorescent markers have been shown to illuminate amyloids (e.g., [26–42]). This includes the luminescent LCO markers commercialised as Amytracker™ 480 and 680 (based on the published molecules HS163 and HS169 [43–45]), developed by Nilsson and colleagues [43, 44, 46–52].

Here we use these stains to provide evidence for a link between T2D as an inflammatory disease and the presence of amyloid proteins. We also assess the effect of different concentrations of LPS-binding protein and the antioxidant L-(-)ergothioneine (see, e.g., [53, 54]) on T2D plasma, and on purified fibrinogen after addition of LPS, to determine if these can decrease amyloid formation and the extent to which this could be shown with the two LCO dyes and ThT (see Fig. 1; infographic of workflow).

Materials and methods
Sample population
The control sample consisted of 17 age- and gender-matched (to the T2D sample) healthy individuals and
an additional 17 young healthy individuals. Inflammation is known to increase with age [55], so we first sought to determine if there were differences between the two control groups (young versus old), to define if age plays a role in our experimental design. This said, it is well-known that the haematological system is only modestly affected by ageing [56]. Exclusion criteria for the healthy samples were: known (chronic and acute) inflammatory conditions such as asthma, human immunodeficiency virus (HIV) or tuberculosis; auto-immune conditions; risk factors associated with metabolic syndrome; smoking; and, if female, being on contraceptive or hormone replacement treatment. This population did not take any anti-inflammatory medication. Based on these exclusion criteria we classified these control donors as ostensibly healthy. We included individuals in our control group that had a range of BMI values, and for some purposes we grouped them as individuals with a BMI of either < 25 (normal BMI) or ≥ 25 (overweight). The distribution of normal versus overweight healthy individuals were: age controlled healthy individuals: < 24.9: 47%; > 25: 53%; and for the younger healthy individuals: < 24.9: 88%; > 25: 12%. Although we included overweight, seemingly healthy individuals in our control group, we recognise that it is well-known that several key inflammatory markers have been consistently associated with obesity, which suggests that a persistent, low-grade, inflammatory response is a potentially modifiable risk factor [57]. Therefore, we acknowledge that overweight apparently healthy individuals may be more prone to low-grade systemic inflammation and that this may impact on their coagulation health.

Our T2D sample consisted of 33 individuals with BMI > 25 (overweight). T2D individuals were voluntarily recruited from a Diabetic Clinic in Somerset West, South Africa. Auto-immune diseases were set as exclusion criteria. Diabetic individuals were diagnosed by an Endocrinologist per the Society for Endocrinology, Metabolism and Diabetes of South Africa Type 2 DiabetesCommittee (SEMSDA) guidelines [58]. These guidelines follow the American Diabetes Association (ADA) criteria to define type 2 diabetes. Demographic data including age, gender, as well as clinical information including haemoglobin A1c (HbA1c) levels and medication used by the T2D patients were obtained. Inclusion criteria consisted of both male and female participants, aged 19 and older, with a diagnosis of T2D for more than 3 months prior to screening and without any signs of infection. Smoking and either contraceptive or hormone replacement treatment were exclusion criteria. Whole blood (WB) of all the participants was obtained in citrate tubes. A platelet poor plasma (PPP) isolate was prepared by centrifuging WB for 15 min at 3000g.

Fluorescent markers and inflammagen binding agents

We aimed to determine if the hypercoagulable clot structure that we have previously noted in T2D and confirmed by staining T2D PPP with thioflavin T (ThT), was indeed amyloid in nature [59]. We have also previously shown that both the LCO dyes Amytracker™ 480 and 680 bind to amyloid areas in clots of healthy PPP exposed to known fibrin–amyloidogenic molecules (viz., iron, lipopolysaccharide (LPS) from gram negative bacteria, and two lipoteichoic acids (LTA1 from Staphylococcus aureus (Sigma, L2515) and LTA2 from Streptococcus pyogenes (Sigma, L3140)) [11]). It was thus of interest to assess if these amyloid markers and ThT will bind to amyloid proteins in clots of T2D in a similar pattern as in the healthy PPP incubated with amyloidogenic molecules that induced amyloidogenic areas (as previously shown in [11]). In addition, we investigated if we could induce a lowered LCO binding in T2D plasma after the addition of LPS-binding protein (LBP) (Abcam, AB119721) and/or an antioxidant compound, ergothioneine (Sigma E7521), to the PPP of T2D (previously we confirmed a reduced binding of ThT in T2D plasma after the addition of LBP [10]). Here, we analysed all diabetes versus controls, but because of the expense and time it takes for the analysis on the confocal microscope, we only looked at a random number of 15 diabetes patents that we additionally exposed to LBP and/or Ergothioneine. We also added LPS followed by LBP to purified fibrinogen to confirm this principle that LPS presence in T2D blood is one of (the main) causes of an amyloidogenic fibrin(ogen) structure (see methods in next section).

The LPS used was from E. coli O111:B4 (Sigma, L2630). A final LPS exposure concentration to plasma and purified fibrinogen of 0.4 ng L⁻¹, and final LPS-binding protein (LBP) exposure concentrations of 8, 20 and 30 ng L⁻¹ were used. A final exposure concentration of 250 µM ergothioneine (Sigma, E7521) was used. Purified fibrinogen (Sigma, F3879) was made up to 0.166 mg mL⁻¹.

Confocal and super-resolution structured illumination (SR-SIM) microscopy of platelet poor plasma (PPP) clots

Platelet poor plasma (PPP) of all healthy and T2D individuals were prepared (as mentioned above), followed by storage at − 80 °C. On the day of analysis, the − 80 °C-stored PPPs were brought to room temperature, followed by a 30-min incubation with ThT at a final concentration of 5 µM and Amytracker™ 480 and 680 (0.1 µL into 100 µL PPP). LBP (8, 20 and 30 ng L⁻¹ final exposure concentration), and ergothioneine (250 µM, final exposure concentration) were also added before addition of fluorescent markers. LBP and/or ergothioneine incubation time was 1 h. Before viewing clots on the confocal microscope, thrombin was added in the ratio 1:2, (5 µL...
thrombin: 10 µL) to create extensive fibrin networks. One clot was prepared for each individual and different random areas were imaged multiple times. Thrombin was provided by the South African National Blood Service, and the thrombin solution was at a concentration of 20 U mL$^{-1}$ and made up in PBS containing 0.2% human serum albumin (see https://www.sigmaaldrich.com/content/dam/sigma-aldrich/docs/Sigma/Product_Information_Sheet/1/t6884pis.pdf for a description of how thrombin units are calculated). A coverslip was placed over the prepared clot, and samples were viewed using a Zeiss LSM 780 with ELYRA PS1 confocal microscope with a Plan-Apochromat 63x/1.4 Oil DIC objective. The following settings were used:

- For ThT: the 488 nm excitation laser was used, with emission measured at 508–570 nm;
- For Amytracker™ 480: the 405 nm excitation laser was used, with emission measured at 478–539 nm; and,
- For Amytracker™ 680: the 561 nm excitation laser was used, with emission measured at 597–695 nm.

A selection of micrographs of the prepared clots were captured. Gain settings were kept the same during all data capture and used for statistical analyses; however, brightness and contrast were slightly adjusted for figure preparation. We captured the fluorescent signal of each of the three fluorescent markers as a composite.czi file in the Zeiss ZEN software and then used ImageJ (FIJI) to split and analyse the RGB channels.

**Quantification of fluorescent staining of clots**

We assessed the variance between (black) background and the presence of fluorescent pixels (binary comparison) for each of the three fluorescent markers in the clots. See [10, 11] for a detailed explanation of the methods. We used the histogram function in ImageJ (FIJI) and calculated the coefficient of variation (CV) (as SD/mean) of the histogram of different pixel intensities as our metric to quantify and discriminate between clots of
Table 1  Demographic data of controls and type 2 diabetes

Healthy individuals (N = 34)

| Gender                      | Age            | BMI: normal: < 24.9; overweight: > 25 |
|-----------------------------|----------------|----------------------------------------|
| Age-controlled healthy      | 61 (± 11)      | < 24.9: 47%; > 25: 53%                 |
| individuals (n = 17)        |                |                                        |
| Female: 82%; Male: 18%      |                |                                        |
| Young healthy individuals   | 22 (± 4)       | < 24.9: 88%; > 25: 12%                |
| (n = 17)                    |                |                                        |
| Female: 24%; Male: 76%      |                |                                        |

Type 2 diabetes individuals (N = 33; BMI: > 25)

| Gender | Age | HbA1c (%) | Chol (mMol L⁻¹) | % with dyslipidaemia | % with hypertension | % with using anti-coagulants |
|--------|-----|-----------|-----------------|----------------------|---------------------|----------------------------|
| Female | 39% | 62 (± 11) | 7 (± 1.2)       | 79                   | 61                  | 55                         |
| Male   | 61% |           |                 |                      |                     |                            |

Statistical analysis was performed with the Mann–Whitney U test, using the STATSDIRECT (version 2.8.0) software.

Table 2  Results from coefficient of variation (CV calculated from confocal micrographs of clots from healthy and diabetes plasma)

Confocal data analysis

Confocal data: young (n = 17) versus old (n = 17) healthy individuals

| Marker          | Healthy clot CV data (age-controlled) | Healthy clot CV data (age-controlled) | P     |
|-----------------|--------------------------------------|--------------------------------------|-------|
| ThT             | 1.30 (± 0.61)                        | 1.42 (± 0.64)                        | P = 0.21 |
| Amytracker 480  | 0.89 (± 0.48)                        | 0.78 (± 1.04)                        | P = 0.08 |
| Amytracker 680  | 1.30 (± 0.46)                        | 1.34 (± 0.77)                        | P = 0.94 |

Confocal data: Age-controlled healthy individuals (n = 17) versus type 2 diabetes individuals (N = 33)

| Marker          | Healthy clot CV data (age-controlled) | Type 2 diabetes clot CV data | P     |
|-----------------|--------------------------------------|-----------------------------|-------|
| ThT             | 1.30 (± 0.61)                        | 2.52 (± 1.16)               | P < 0.0001 |
| Amytracker 480  | 0.89 (± 0.48)                        | 1.44 (± 0.50)               | P < 0.0001 |
| Amytracker 680  | 1.30 (± 0.46)                        | 2.30 (± 0.67)               | P < 0.0001 |

Confocal data: Treated versus untreated diabetes data (n = 15)

| Marker          | Untreated T2D                        | T2D plasma treated with 8 ng L⁻¹ LBP and 250 µM ergothioneine | P     |
|-----------------|-------------------------------------|----------------------------------------------------------------|-------|
| ThT             | 2.23 (± 1.21)                       | 1.58 (± 0.78)                                                    | P = 0.0008 |
| Amytracker 480  | 1.25 (± 0.42)                       | 1.25 (± 0.54)                                                    | P = 0.37 |
| Amytracker 680  | 1.91 (± 0.73)                       | 1.37 (± 0.55)                                                    | P = 0.0009 |

| Marker          | Untreated T2D                        | T2D plasma treated with 20 ng L⁻¹ LBP and 250 µM ergothioneine | P     |
|-----------------|-------------------------------------|----------------------------------------------------------------|-------|
| ThT             | 2.23 (± 1.21)                       | 1.75 (± 0.61)                                                    | P = 0.007 |
| Amytracker 480  | 1.25 (± 0.42)                       | 0.90 (± 0.34)                                                    | P = 0.0001 |
| Amytracker 680  | 1.91 (± 0.73)                       | 1.50 (± 0.37)                                                    | P = 0.0002 |

| Marker          | Untreated T2D                        | T2D plasma treated with 30 ng L⁻¹ LBP                           | P     |
|-----------------|-------------------------------------|----------------------------------------------------------------|-------|
| ThT             | 2.23 (± 1.21)                       | 1.87 (± 0.60)                                                    | P = 0.033 |
| Amytracker 480  | 1.25 (± 0.42)                       | 1.45 (± 2.98)                                                    | P = 0.036 |
| Amytracker 680  | 1.91 (± 0.73)                       | 1.70 (± 0.60)                                                    | P = 0.042 |

Statistical analysis was performed with the Mann–Whitney U test, using the STATSDIRECT (version 2.8.0) software.
healthy (age-controlled) naïve PPP and clots from T2D individuals. Figure 2 gives an example of the 3 marker histograms (Amytracker™ 480, 680 and ThT). CVs were calculated from the data shown at the bottom of each histogram.

**Structured illumination super-resolution (SR-SIM) microscopy**

We also prepared structured illumination super-resolution (SR-SIM) microscopy [60] Z-stacks of T2D clots and compared the T2D clots to clots where we previously added known amyloidogenic molecules (iron, LPS, LTA1 and LTA2) to PPP from healthy donors (unpublished data from [11]). Previously, we incubated the four candidate amyloidogenic molecules for 1 h before adding the three fluorescent markers.

**Statistical analysis**

Sample analysis was performed by the Mann–Whitney U test, using the STATSDIRECT (version 2.8.0) software and with GraphPad Prism (version 5.0) and one-way ANOVA with the Kruskal–Wallis non-parametric test and the Dunns post-test.

**Results**

Table 1 shows demographics of our control groups and T2D sample, while Table 2 shows CV results which are calculated by using the mean and SD of the fluorescence for each of the three fluorescent markers in the different clots (Materials and Methods). There were no significant differences in CVs for the three markers when we compared the young and the old control PPP clot structure, and we therefore conclude age does not appear to influence our experimental design. However, there were significant differences in CVs for all three markers when the healthy (age-matched) individuals and T2D clots were compared. Figures 3 and 4 show confocal microscopy of PPP for representative clots from healthy and T2D samples. Figure 5 shows SR-SIM z-stacks of a representative T2D clot and also that of a healthy individual with added LPS, LTA1 and LTA2 (unpublished data from [11]). In addition, we did not find significant differences between our normal and overweight BMI control groups, therefore in this paper, we group both the normal BMI and overweight individuals as the control sample for the T2D sample.

The clots from the T2D patients most resemble that of the controls incubated with LPS. We have previously
suggested that the potent inflammagens LPS and LTA can cause aberrant clot formation where the fibrin(ogen) protein becomes amyloid(ogenic) after exposure to these inflammagens [11]. In this paper, our results show that in T2D, amyloidogenesis is also present, as confirmed by the 2 LCO markers, and are similar to clots from healthy individuals but where LPS and LTA had been added prior to coagulation. We thus suggest that this aberrant morphology may (at least in part), be due to the presence of bacterial inflammagens in T2D blood.

We also added various concentrations of LPS-binding protein (LBP) and the antioxidant ergothioneine to T2D plasma to determine if the amyloid signal from the LCO dyes will be reduced. See Table 2 for the results as well as Fig. 6 for confocal data. These results show a dose-response in the reduction of fluorescent signal as seen with CV data. LBP breaks up the amyloid signal, where fewer large fluorescent amyloid clumps are noted, but rather more small fluorescent spots are seen (see Fig. 6). These data also show rather clearly the differences of detail between the binding (sites) of the three fluorophores. Ergothioneine does not significantly reduce the amyloid by itself; however, the effects of the addition of other antioxidants needs to be explored further (Fig. 7). Figure 8 shows a comparison of the confocal results [(CVs) of the various LBP exposures to T2D plasma (8,
Pretorius et al. Cardiovasc Diabetol (2017) 16:141

Page 8 of 14

20 and 30 ng L\(^{-1}\) LBP], using a one-way ANOVA with the Kruskal–Wallis non-parametric test and the Dunns post-test.

Purified fibrinogen with added 0.4 ng L\(^{-1}\) LPS followed by increasing concentrations of LBP with and without ergothioneine showed the same trends, where the amyloid signal was dispersed and appeared as small fluorescent spots (see Fig. 9).

**Discussion**

T2D is one of many chronic, inflammatory diseases, and as such, shares a variety of hallmarks with these other conditions. These include the presence of inflammatory cytokines, iron dysregulation, and various coagulopathies [61–65]. What has not been clear is the actual cause of this inflammation; that is, what are the stimulating molecules to which inflammation is a response? Such a cause must exist, as there is otherwise little reason why the inflammation might happen ‘spontaneously’ in a way that it does not in healthy individuals. A strong candidate cause of such systemic inflammation may lie in a dormant microbiome that can shed inflammagens. In nature, most microbes exist in a dormant, non-replicating state, and as such are typically difficult to culture using standard microbiological culture techniques (e.g. [66, 67]).

A lack of culturability may mean that a cell is non-viable under the circumstances tested, but they might be culturable in that they may be induced to return to a state of culturability (by a process or processes typically referred to as ‘resuscitation’) [66, 67].

We have suggested [68–71] that the source of these inflammagens is in fact populations of dormant microbes that are resident in blood and tissues, and that can occasionally ‘wake up,’ often in response to bioavailable iron, whereupon they shed known, potent inflammagens such as LPS and LTA [11]. LPS has also been specifically implicated in T2D pathology [18–25, 72]. It is suggested that LPS may contribute to low-grade systemic inflammation in insulin-resistant states, and it is also now accepted that specifically gut bacteria is the sources of LPS [24]. In T2D it is well-known that there is an increased intestinal permeability in the genesis of T2D [73–75], and that this can be the origin for LPS.

We have also shown, using scanning electron microscopy (e.g. [1, 8, 69, 76–78], that in many cases a particular manifestation of the coagulopathies accompanying these diseases is the clotting of blood into a highly anomalous form. The above two strands of work led to the idea that the anomalous clotting might in fact be caused by the presence of low concentrations of bacterial–derived LPS, and this turned out to be the case when we tested the addition of extremely low concentrations of LPS to PPP from healthy individuals [9]. Further [9, 77], the fact that these clots could be stained with the amyloid stain thioflavin T, and blocked by the addition of LBP, strongly suggested (i) that the anomalous clotting was amyloid
Fig. 6 Clots from a representative type 2 diabetes individual with added LPS-binding protein (LBP) and ergothioneine, and fluorescent markers. a Naive T2D clot; b 8 ng L\(^{-1}\) LBP and 250 µM ergothioneine; c 20 ng L\(^{-1}\) LBP and 250 µM ergothioneine d 30 ng L\(^{-1}\) LBP. Fluorescence shown from left to right Amytracker 680 (red), Amytracker 480 (blue) and ThT (green)
in nature, and (ii) that LPS (and the potent inflamma-
gen LTA from Gram-positive bacteria) could indeed be
a typical culprit. We recently showed that both LPS and
LTA and also iron, cause healthy fibrin(ogen) to become
amyloidogenic, and we used Amytracker ™ 480, 680 and
ThT in these experiments [11]. We found that the nature
of the staining efficiencies also varied depending on the
inflammagen added, with LTA particularly leading to
preferential staining by Amytracker ™ 680.

A logical corollary of the above, then, was that the
anomalous clotting seen in PPP from patients with
chronic inflammatory diseases might also be due (at least
in part) to the presence of LPS, and that this too might
be reversed by the addition of LBP. We had illustrated
this previously using the common stain thioflavin T [59,
77] and here show it further using a variety of micro-
scopic techniques, together with two novel stains, viz.
Amytracker ™ 480 and Amytracker ™ 680. In all cases,
there was a very substantial staining of the PPP from
T2D patients, and this was removed, in a dose-dependent
fashion, by the pre-incubation of the PPP with relatively
low concentrations of lipopolysaccharide binding protein.
In addition, the detailed nature of the staining varied for
the three stains, suggested that they had both common
and separate binding sites, with the two Amytracker ™
stains being the most potent stains.

Ergothioneine is a potent antioxidant that is resistant to
autoxidation [53, 54]. However, it was without effect on
the amyloid staining, suggesting that there is no redox-
dependent basis for these effects. This said, the effects of
the addition of other antioxidants and/or polyphenolic
compound need to be explored further.

Overall, we have shown very clearly that there is a sub-
stantial potential for amyloidogenesis when the plasma
of individuals with T2D is clotted, and that this can be
prevented by preincubation of the PPP with lipopolysac-
charide-binding protein. This suggests very strongly that
there is indeed a microbial component involved in the

![Fig. 7](image1)

T2D with added 250 µM ergothioneine. Fluorescence shown from left to right Amytracker 680 (red), Amytracker 480 (blue) and ThT (green)

![Fig. 8](image2)

Graph drawn from the confocal results [(CVs) of the various LBP exposures to type 2 diabetes (8, 20 and 30 ng L⁻¹ LBP]. Sample analysis was performed with GraphPad Prism (version 5.0) and one-way ANOVA with the Kruskal–Wallis non-parametric test and the Dunns post-test

|          | Blue: AmyTracker 480 | Red: AmyTracker 680 | Green: ThT |
|----------|----------------------|---------------------|-----------|
| 8 ng·L⁻¹ vs 20 ng·L⁻¹ | < 0.0001             | NS                  | NS        |
| 8 ng·L⁻¹ vs 30 ng·L⁻¹ | NS                   | 0.045               | 0.0315    |
| 20 ng·L⁻¹ vs 30 ng·L⁻¹ | < 0.0001             | NS                  | NS        |
development of T2D and its sequelae. Of course there are potentially other circulating inflammatory molecules in T2D blood that might contribute to the amyloidogenic fibrin(ogen) structure, and some may include iron, LTA, SAA and upregulated cytokines. However, in this paper, we show that LPS/LTA is one of the important inflammagens in T2D, and the LBP removes most of the molecules that causes the amyloid formation in fibrin(ogen). Considering that amyloids can be cytotoxic, and many of the sequelae of chronic T2D involve damage to cells of other tissues such as the kidney (nephropathies) and the eye (retinopathies), it is at least reasonable that treatments designed either to remove the dormant microbes or the use of LBP to remove their cell wall products might be of therapeutic benefit. This is an important question for the future.

**Fig. 9**  
(a) Purified fibrinogen with 0.4 ng L\(^{-1}\) LPS and added thrombin  
(b) Purified fibrinogen with 0.4 ng L\(^{-1}\) LPS followed by 30 ng L\(^{-1}\) LBP and thrombin  
(c) Purified fibrinogen with 0.4 ng L\(^{-1}\) LPS and 250 µM ergothioneine followed by thrombin. Fluorescence shown from left to right: Amytracker 680 (red), Amytracker 480 (blue) and ThT (green)

**Authors' contributions**  
EP Studyleader, confocal analysis draft and critical revision of paper. MJP Acquisition and analysis of all data, editing of paper. LE Technical assistance on confocal microscope. GCE Endocrinologist; clinical advisor. DBK Co-study leader and critical revision of paper. All authors read and approved the final manuscript.

**Author details**  
1 Department of Physiological Sciences, Faculty of Health Sciences, Stellenbosch University, Stellenbosch Private Bag X1 Matieland, Stellenbosch 7602, South Africa.  
2 Central Analytical Facility, Stellenbosch University, Stellenbosch Private Bag X1 Matieland, Stellenbosch 7602, South Africa.  
3 Synexus Helderberg Clinical Research Centre, Helderberg Synexus South Africa, 7G&H Arun Place, Somerset West 7130, South Africa.  
4 School of Chemistry and Manchester Institute of Biotechnology, The University of Manchester, 131 Princess St, Manchester M1 7DN, Lancs, UK.

**Acknowledgements**  
We thank the diabetes clinic and sister Laura Botha for diabetes patient blood collection and Dr Theo Nell for control blood collection, as well as Retha Engelbrecht for data capturing assistance.
Competing interests
The authors declare the following patent application: Method for treating Diabetes (ZA2017/05546).

Availability of data and materials
Raw data, including original micrographs can be accessed at: https://drms/ft/1AgOCmY3BkHk0EgzbP3pgV1Yr or https://www.researchgate.net/profile/Etheresia_Pretorius.

Consent for publication
All authors give consent for publication.

Ethics approval and consent to participate
This study was approved by the Ethical Committee of the University of Pretoria (South Africa) and Stellenbosch University: Ethics Clearance Number: 298/2016. We adhered strictly to the Declaration of Helsinki. A written form of informed consent was obtained from all donors (available on request). Blood was collected and methods were carried out in accordance with the relevant guidelines of the ethics committee.

Funding
Biotechnology and Biological Sciences Research Council (Grant BB/L025752/1); National Research Foundation (NRF) of South Africa (91548: Competitive Program) and Medical Research Council (MRC) of South Africa (Self-Initiated Research Program 2017 to 2019). Grant holder: E Pretorius.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 8 September 2017   Accepted: 23 October 2017
Published online: 02 November 2017

References
1. Pretorius E, Kel DB. Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases. Integr Biol. 2014;6:486–510.
2. Bester J, Pretorius E. Effects of IL-1β, IL-6 and IL-8 on erythrocytes, platelets and clot viscoelasticity. Sci Rep. 2016;6:32188.
3. Pretorius E, du Plooy JN, Bester J. Erythrocytes and their role as health indicator: using structure in a patient-oriented precision medicine approach. Blood Rev. 2016;30(4):263–74.
4. Gasparyan AY, Ayvazyan L, Pretorius E, Kitas GD. Platelets in rheumatic diseases: friend or foe? Curr Pharm Des. 2014;20(4):552–66.
5. Soma P, Swaneepol AC, du Plooy JN, Mpcopo T, Pretorius E. Flow cytometric analysis of platelets type 2 diabetes mellitus reveals ‘angry’ platelets. Cardiovasc Diabetol. 2016;15(1):52.
6. Van Der Spuy WJ, Pretorius E. A place for ultrastructural analysis of platelets in cerebral ischemic disease. Microsc Res Tech. 2013;76(8):795–802.
7. Bell DB, Pretorius E. The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrinogen. J Integr Biol. 2015;7:24–52.
8. Pretorius E, Mbotwe S, Bester J, Robinson CJ, Kell DB. Acute induction of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation: the central roles of LPS and LPS-induced cell death. Integ Biol. 2015;7:1339–77.
9. Schwandner R, Dziasi R, Wescie H, Rothe M, Kirchning CJ. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem. 1999;274(25):17406–9.
10. Creely SJ, McTernan PG, Kusminskij CM, Fisher M, Da Silva NF, Khanolkar M, Evans M, Harte AL, Kumar S. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292(3):E740–7.
11. Hawkesworth S, Moore SE, Fulford AJ, Barclay GR, Darboe AA, Mark H, Nyan OA, Prentice AM. Evidence for metabolic endotoxemia in obese and diabetic Gambian women. Nutr Diabetes. 2013;3.e63.
12. Nymann M, Pussinen P, Tuomainen AM, Forsblom C, Gropp PH, Lehto M. Serum lipopolysaccharide activity is associated with the progression of kidney disease in patients with type 1 diabetes. Diabetes Care. 2009;32(9):1689–93.
13. Vérgés B, Duvidillard L, Lagrost L, Vachoux C, Garret C, Bouyer K, Courtne M, Pomé C, Burcelin R. Changes in lipoprotein kinetics associated with type 2 diabetes affect the distribution of lipopolysaccharides among lipoproteins. J Clin Endocrinol Metab. 2014;99(7):E1245–53.
14. Zaman GS, Zaman F. Relationship between postprandial endotoxemia in nonobese postmenopausal women and diabetic nonobese postmenopausal women. J Nat Sci Biol Med. 2015;6(1):89–93.
15. Al-Attas OS, Al-Daghri NM, Al-Rubeaaisa K, da Silva NF, Sabico SL, Kumar S, McTernan PG, Harte AL. Changes in endotoxin levels in T2D subjects on anti-diabetic therapies. Cardiovasc Diabetol. 2009;8:20.
16. Jayashree B, Bibin YS, Prabhu D, Shanthirani CS, Gokulakrishnan K, Lakshmi BS, Mohan V, Balasubramanyam M. Increased circulatory levels of lipopolysaccharide (LPS) and zonulin signify novel biomarkers of proinflammation in patients with type 2 diabetes. Mol Cell Biochem. 2014;388(1–2):203–10.
17. Pussinen P, Haulumina AS, Lehto M, Sundvall J, Salomaa V. Endotoxemia is associated with an increased risk of incident diabetes. Diabetes Care. 2011;34(2):392–7.
18. Maecawa I, Hong HS, Liu R, Wu CY, Cheng RH, Kung MP, Kung HF, Lam KS, Oddo S, Laferla FM, et al. Congo red and thioflavin-T analogs detect Abeta oligomers. J Neurochem. 2008;104(2):457–68.
19. Chang WM, Dakarani M, Capule CC, Sigurdsson CJ, Fang J, Theodorakis EA. ANCA: a family of fluorescent probes that bind and stain amyloid plaques in human tissue. ACS Chem Neurosci. 2011;2(5):249–55.
20. Giorgadze TA, Shiina N, Baloch ZW, Tomaszewski JE, Gupta JK. Improved staining of diverse amyloid fibrils in vitro by the fluorescent dye Nile red. J Mol Biol. 2007;370(5):727–33.
21. Mirza R, Sjolander D, Hammarström P. Spectroscopic characterization of diverse amyloid fibrils in vitro by the fluorescent dye Nile red. Mol Biol Symp. 2011;7(1):122–40.
22. Shen D, Coleman J, Chan E, Nicholson TP, Dai L, Sheppard PW, Patton WF. Novel cell- and tissue-based assays for detecting misfolded and
aggregated protein accumulation within aggresomes and inclusion bod-
ies. Cell Biochem Biophys. 2011;60(3):173–85.

34. Easterhoff D, DiMaio JM, Liyanage W, Lo CW, Bae W, Doran TM, Smrcka A, Nilsson BL, Dewhurst S. Fluorescence detection of caticonic amyloid fibrils in human semen. Bioorg Med Chem Lett. 2013;23(18):S199–202.

35. Kovalská VB, Vostykyy MV, Tomlachev OI, Sîlînski YL, Segres-Nolten GM, Subramaniam V, Yarmoluk SM. Tri- and pentamethine cyanine dyes for fluorescent detection of alpha-synuclein oligomeric aggregates. J Fluoresc. 2012;22(6):1441–8.

36. Omo N, Watanabe H, Kimura H, Saji H. BODIPY-based molecular probe for imaging of cerebral beta-amyloid plaques. ACS Chem Neurosci. 2012;3(4):319–24.

37. Rajasekhar K, Narayanaswamy N, Munugan NA, Kuang G, Ageren H, Govindaraju T. A high affinity red fluorescence and colorimetric probe for amyloid beta aggregates. Sci Rep. 2016;6:23668.

38. Watanabe H, Omo M, Matsumura K, Yoshimura M, Kimura H, Saji H. Molecular imaging of beta-amyloid plaques with near-infrared boron dipyrromethene (BODIPY)-based fluorescent probes. Mol Imaging. 2013;12(5):338–47.

39. Yuan L, Lin W, Zheng K, He L, Huang W. Far-red to near infrared analyte-
responsive fluorescent probes based on organic fluorophore platforms for fluorescent imaging. Chem Soc Rev. 2013;42(2):622–61.

40. Guo Z, Park S, Yuan J, Shin I. Recent progress in the development of near-infrared fluorescent probes for biomaging applications. Chem Soc Rev. 2014;43(1):16–29.

41. Staderini M, Martin MA, Bolognesi ML, Menéndez JC. Imaging of beta-amyloid plaques by near infrared fluorescent tracers: a new frontier for chemical neuroscience. Chem Soc Rev. 2015;44(7):1807–19.

42. Zhang A, Tian Y, Zhang C, Tian X, Ross AW, Moir RD, Sun H, Tanzi RE, Moore A, Ran C. Near-infrared fluorescent molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer’s disease. Proc Natl Acad Sci USA. 2015;112(31):9734–9.

43. Klingstedt T, Nilsson KP. Luminescent conjugated poly- and oligo-thio-
ephones: optical ligands for spectral assignment of a plethora of protein aggregates. Biochem Soc Trans. 2012;40(4):704–10.

44. Magnusson K, Simon RA, Sjölander D, Sigurdson CJ, Hammarström P, Nilsson KP. Multimodal fluorescence microscopy of prion strain specific PKP deposits stained by thiophene-based amyloid ligands. PloS One. 2014;8(4):1–10.

45. Shirani H, Linareis M, Sigurdson CJ, Lindgren M, Norman P, Nilsson KP. A palette of fluorescent thiophene-based ligands for the identification of protein aggregates. Chemistry (Weinhim an der Bergstrasse, Germany). 2015;21(43):13333–7.

46. Åslund A, Sigurdson CJ, Klingstedt T, Grathwohl S, Bolmont T, Dickstein DL, Glimsdal E, Prokop S, Lindgren M, Konradsson P, et al. Novel penta-
meric fluorescent probes based on organic fluorophore platforms for fluorescent imaging. Chem Chem. 2015;2015;21(43):15133–7.

47. Klingstedt T, Nilsson KP. Luminescent conjugated oligothiophenes for sensitive fluorescent assignment of protein aggregates. Cell Biochem Biophys. 2011;60(3):173–85.

48. El Assar M, Angulo J, Rodriguez-Manas L. Oxidative stress and vascular inflammation in aging. Free Radical Biol Med. 2013;65:380–401.

49. Lichtman MA, Williams WJ. Hematology in the aged. In: Ernest Beutler MAL, Coller BS, Kipps TJ, Seligson U, editors. Williams Hematology. Chap 8. 6th ed. USA: McGraw-Hill, 2001.

50. Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut micro-
biora. Lancet Diabetes Endocrinol. 2015;3(3):207–15.

51. SEMSDA. The 2017 SEMSDA guideline for management of Type 2 diabe-
tes guideline committee. JEMDSA. 2017;21(1):51–196.

52. Pretorius E, Mbtotwe S, Kell DB. Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson’s disease: implications for its aetiology. bioRxiv preprint archive 2017. doi:10.1101/124180.

53. El Assar M, Angulo J, Rodriguez-Manas L. Oxidative stress and vascular inflammation in aging. Free Radical Biol Med. 2013;65:380–401.

54. Lichtman MA, Williams WJ. Hematology in the aged. In: Ernest Beutler MAL, Coller BS, Kipps TJ, Seligson U, editors. Williams Hematology. Chap 8. 6th ed. USA: McGraw-Hill, 2001.

55. Cox AJ, West NP, Cripps AW. Obesity, inflammation, and the gut micro-
biora. Lancet Diabetes Endocrinol. 2015;3(3):207–15.

56. SEMSDA. The 2017 SEMSDA guideline for management of Type 2 diabe-
tes guideline committee. JEMDSA. 2017;21(1):51–196.

57. Pretorius E, Mbtotwe S, Kell DB. Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson’s disease: implications for its aetiology. bioRxiv preprint archive 2017. doi:10.1101/124180.
75. Sato J, Kanazawa A, Watada H. Type 2 diabetes and bacteremia. Ann Nutr Metab. 2017;71(Suppl 1):17–22.

76. Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metalomics. 2014;6(4):749–73.

77. Kell DB, Pretorius E. Proteins behaving badly. Substoichiometric molecular control and amplification of the initiation and nature of amyloid fibril formation: lessons from and for blood clotting. Prog Biophys Mol Biol. 2017;123:16–41.

78. Pretorius E, Bester J, Vermeulen N, Alummoottil S, Soma P, Buys AV, Kell DB. Poorly controlled type 2 diabetes is accompanied by significant morphological and ultrastructural changes in both erythrocytes and in thrombin-generated fibrin: implications for diagnostics. Cardiovasc Diabetol. 2015;14:30.